Condition (MeSH)
Prostatic Intraepithelial Neoplasia
ClinicalTrials.gov lists 8 trials for Prostatic Intraepithelial Neoplasia or a narrower condition beneath it. GTx has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 8 trials are tagged with Prostatic Intraepithelial Neoplasia itself; the rest are tagged with a narrower condition beneath it.
When did Prostatic Intraepithelial Neoplasia trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2015 | 1 |
| 2006 | 1 |
| 2005 | 3 |
| 2004 | 1 |
| 2003 | 1 |
| 2001 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 8 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Prostatic Intraepithelial Neoplasia trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Not applicable | 2 |
| Observational | 1 |
How many Prostatic Intraepithelial Neoplasia trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 6 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Prostatic Intraepithelial Neoplasia trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| GTx | 2 |
| ProteoSys AG | 1 |
Which serious adverse events do Prostatic Intraepithelial Neoplasia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Coronary artery disease | 22 | 1 |
| Osteoarthritis | 15 | 1 |
| Pneumonia | 11 | 1 |
| Localised osteoarthritis | 10 | 1 |
| Urosepsis | 10 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Prostatic Intraepithelial Neoplasia? (21)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial. | Radiology | 2023 | Yes |
| Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. | Oncotarget | 2016 | Yes |
| Early experience with multiparametric magnetic resonance imaging-targeted biopsies under visual transrectal ultrasound guidance in patients suspicious for prostate cancer undergoing repeated biopsy. | Scandinavian journal of urology | 2015 | Yes |
| Advantages of single-puncture transperineal saturation biopsy of prostate: analysis of outcomes in 125 patients using our scheme. | International urology and nephrology | 2015 | Yes |
| Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. | Cancer prevention research (Philadelphia, Pa.) | 2015 | Yes |
Showing 5 of 21 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.